"id:ID","uuid","studyVersion","studyRationale","id","studyAcronym","studyTitle"
"821","faf617bb-7f32-456f-8930-4a6cdc00abe7","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","H2Q-MC-LZZT","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease"
